A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is trying to find the highest amount of a medicine called ION251 that people with a type of cancer called multiple myeloma can safely tolerate. They also want to figure out the best amount to use in the next phase of testing.
This study is trying to find the highest amount of a medicine called ION251 that people with a type of cancer called multiple myeloma can safely tolerate. They also want to figure out the best amount to use in the next phase of testing.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: